person
as of 2026-07-01Pierre-Michel Llorca, MD PhD
at a glance
Roles: Principal Investigator, Author
KOL signal score 9
3 publications · 2 high-value
Cross-drug reach: 2 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
University Hospital, Clermont-Ferrand
Roles
Principal Investigator, Author
KOL signal
9
Publications
3 (2 high-value)
Trial investigator
no
Publishes on
2 drugs
Trials led
1
Influence of Environmental Factors and Schizophrenia
NCT03296384—Unknown
Publications & congress
3
Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials.
Advances in therapy · 2025 · high-value
QT Interval, Antipsychotics and Correlates Among Patients with Schizophrenia: Cross-Sectional Data from the Multicentric Real-World FACE-SZ.
Drug safety · 2025 · high-value
Real-world effectiveness of antipsychotic polytherapy on rehospitalization in psychotic disorders: A French nationwide cohort analysis.
Comprehensive psychiatry · 2026
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
drug
PRINCIPAL_INVESTIGATOR